De-escalation of Treatment in Metastatic Renal Cell Carcinoma: Why? How? Who? When?
Fabien Moinard-Butot, Simon Nannini, Gwénaëlle Gravis, Marie Pautas et autres
0 citationsClinical Genitourinary Cancer
Simon Nannini
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
33Publications signalées
128Citations signalées
6Affiliations récentes
Institutions déclarées
Domaines associés
Sarcoma Diagnosis and TreatmentRenal cell carcinoma treatmentCancer Immunotherapy and BiomarkersCancer-related Molecular PathwaysGenomics, phytochemicals, and oxidative stress
Publications récentes
In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-dependent cytotoxicity
Simon Nannini, Celine Sieffert, Andrew McGown, Xin-Yue Gao et autres
0 citationsFigshare
In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-dependent cytotoxicity
Simon Nannini, Celine Sieffert, Andrew McGown, Xin-Yue Gao et autres
0 citationsFigshare
In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-dependent cytotoxicity
Simon Nannini, Celine Sieffert, Andrew McGown, Xin-Yue Gao et autres
0 citationsJournal of Enzyme Inhibition and Medicinal Chemistry
In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-dependent cytotoxicity
Simon Nannini, Celine Sieffert, Andrew McGown, Xin-Yue Gao et autres
0 citationsFigshare
Toxicités cardiovasculaires des principales thérapies ciblées orales dans les tumeurs solides
Simon Nannini, Clément Droesch, Émilie Schultz, Fabien Moinard-Butot
0 citationsBulletin du Cancer
Evolution of bispecific and multispecific antibodies in cancer therapy
Elisa Fontana, Rafael Grochot, Nuria Kotecki, Bernard Doger et autres
2 citationsThe Lancet Regional Health - Europe
Geneo study: Comprehensive genomic profiling versus limited local reimbursed NGS panels within the belgian Precision initiative
Gordana Raiceivc Toungouz, Aline Hébrant, Simon Nannini, Cédric Van Marcke et autres
0 citationsEuropean Journal of Cancer
A retrospective evaluation of treatment patterns following cabozantinib treatment for advanced renal cancer: The CABONEXT study.
Simon Nannini, Fabien Moinard-Butot, Dorian Bochaton, P. Bigot et autres
0 citationsJournal of Clinical Oncology
Adjuvant endocrine therapy in high-risk HR-positive and HER2-negative early breast cancer
T. Reverdy, Simon Nannini, Gilles Freyer, Pauline Corbaux
0 citationsAcademia oncology.
Innovative Research Organization to Facilitate Clinical Trials Implementation in the Era of Molecular Oncology: The Spiderweb Model of the Oncodistinct Network
Simon Nannini, A Gonçalves, Carlos Gomez‐Roca, Demetris Papamichael et autres
0 citationsJCO Precision Oncology
First Interim Analysis of the CABONEXT Study: A Retrospective Evaluation of Treatment Patterns Following Cabozantinib Treatment for Advanced Renal Cancer
Simon Nannini, Fabien Moinard‐Butot, Sylvain Ladoire, Dorian Bochaton et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.